BOSTON, Sept. 9, 2024 /PRNewswire/ -- Bambusa Therapeutics Inc., a biotechnology company focused on developing bispecific antibodies for the treatment of immunological and inflammatory (I&I) disorders ...
Bambusa has successfully advanced two differentiated bispecific programs—BBT001 and BBT002—into the clinic within 12 months of the company's founding, underscoring its execution-first culture and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback